The release notes that household exposure to SARS-CoV-2 is thought to result in up to >20-fold increased risk of infection. For household contacts and caregivers of known COVID-19 patients, the company says, the researchers anticipate that probiotics show promise to:
- Reduce the risk of SARS-CoV-2 infection
- Reduce the severity of COVID-19 disease
- Reduce symptoms
Lactobacillus rhamnosusGG was specifically selected to be included in the study based on evidence from over 200 clinical trials that have proven its health benefits, including immune support, according to the release, which specifies that select findings have demonstrated the strain's help in preventing ventilator-associated pneumonia in adult patients and decreasing risk of upper respiratory tract infections in children attending day care.